DBS Surgery vs Medication for Parkinson’s: How Do You Know Which Option Is Right?

For most Parkinson’s patients, medication works well in the early years. Levodopa restores dopamine signalling reliably, and with the right dose timing, motor symptoms stay largely controlled. The problem is that levodopa’s therapeutic window narrows over time, typically within 5 to 10 years of starting treatment, producing motor fluctuations where wearing-off periods become unpredictable and peak-dose dyskinesias make the medication itself a source of disability.

According to Dr. Guruprasad Hosurkar, a leading neurologist in Bangalore,
“The question is never DBS versus medication in isolation. It is whether the patient has reached the point where medication can no longer provide stable motor control across the day. When someone is spending more than 25% of their waking hours in the off state despite optimised drug therapy, that is the conversation where DBS becomes the more logical next step rather than adding yet another medication to an already complex regimen.”

Levodopa remains the most effective symptomatic treatment for Parkinson’s disease, but its limitations become clinically significant as the disease progresses. Understanding where medication reaches its ceiling helps patients and families recognise when a surgical evaluation makes sense rather than waiting until function has declined considerably further.

• Motor fluctuations signal narrowing levodopa window: As dopaminergic neurons continue to deplete, the brain loses its ability to buffer levodopa between doses, producing predictable wearing-off episodes and increasingly unpredictable on-off switches that no dose adjustment fully resolves.
• Dyskinesias indicate peak-dose toxicity from high levodopa loads: Involuntary writhing movements at peak medication effect affect up to 40% of patients within 5 years of starting levodopa, and managing them by reducing the dose simply brings back the off-state symptoms that the medication was controlling.
• Pill burden and timing rigidity reduce quality of life significantly: Patients on advanced medical therapy often take 5 to 8 doses per day with strict timing requirements, building their entire daily schedule around medication windows in a way that makes normal social and professional life increasingly difficult.
• Levodopa does not address non-motor progression: Autonomic dysfunction, cognitive change, and sleep disorders all progress independently of dopamine replacement, and continuing to increase medication doses does not slow any of these, making the risk-benefit calculation of adding more drugs progressively less favourable. A detailed look at what to expect from the surgical option is covered under DBS surgery.

Recognising this plateau early, rather than waiting for complete functional decline, is what gives patients the best outcomes from any escalation in treatment.

Deep Brain Stimulation works through a fundamentally different mechanism to oral medication. Rather than supplementing dopamine levels that fluctuate with each dose, DBS delivers continuous, programmable electrical stimulation to the subthalamic nucleus or globus pallidus, stabilising the abnormal circuit activity that drives motor symptoms regardless of medication timing.

• Continuous stimulation eliminates on-off fluctuations: DBS provides round-the-clock motor control without the peaks and troughs of oral levodopa, extending stable on time by an average of 4 to 6 hours per day in well-selected patients according to clinical trial data.
• DBS reduces dyskinesias by allowing levodopa dose reduction: Because motor control no longer depends entirely on high levodopa doses, most patients reduce their total daily levodopa equivalent dose by 30 to 60% after DBS, which directly reduces peak-dose dyskinesias without sacrificing motor benefit.
• Adaptive closed-loop DBS adjusts stimulation in real time: Unlike conventional DBS that delivers fixed stimulation, adaptive systems read brain signals continuously and modulate output accordingly, a technology now available in Bangalore through DBS surgery for Parkinson’s disease that produces more precise symptom control with fewer stimulation-related side effects.
• Candidacy requires careful selection to achieve best outcomes: Patients under 70 with good levodopa responsiveness, at least 4 years of disease duration, significant motor fluctuations, and preserved cognition gain the most from DBS, while those with prominent gait freezing, dementia, or poor levodopa response are unlikely to see meaningful benefit from surgery alone.

The decision between continuing optimised medication and proceeding to DBS is not a crisis decision – it is a planned, structured evaluation that works best when it happens before the patient has lost significant function waiting for things to improve on their own.

Dr. Guruprasad Hosurkar leads the Movement Disorders and Parkinson’s Disease Programme at KIMS Hospital, Mahadevapura, where he established India’s first Adaptive Closed-Loop DBS centre. His clinical approach to the DBS versus medication decision combines rigorous candidacy assessment with honest outcome counselling, so patients understand exactly what each option can and cannot deliver before any surgical decision is made.